Trial Profile
A study to evaluate biomarkers for eculizumab in patients with atypical hemolytic uremic syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2015
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Biomarker; Therapeutic Use
- 30 Jun 2015 New trial record